To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)—Market-Insight,-Epidemiology-and-Market-Forecast-2027
Oct 22, 2018 | Reading Time: < 1 minute
To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)—Market-Insight,-Epidemiology-and-Market-Forecast-2027
FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...
Find MoreOctober, worldwide, is designated as the Breast cancer awareness month. Pink ribbons. Pink colored tee-shirts. Pink banners. Going pink, wearing pink - the whole month is devoted to raising awareness about breast cancer in women. Healthcare institutions, pharmaceutical companies, and federations all over dedicatedl...
Find MoreAZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.